样式: 排序: IF: - GO 导出 标记为已读
-
Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-03 Markus H Hoffmann, Henriette Kirchner, Gerhard Krönke, Gabriela Riemekasten, Michael Bonelli
Due to optimised treatment strategies and the availability of new therapies during the last decades, formerly devastating chronic inflammatory diseases such as rheumatoid arthritis or systemic sclerosis (SSc) have become less menacing. However, in many patients, even state-of-the-art treatment cannot induce remission. Moreover, the risk for flares strongly increases once anti-inflammatory therapy is
-
Novel autoantibodies help diagnose anti-SSA antibody negative Sjögren disease and predict abnormal labial salivary gland pathology Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-03 Maxwell Parker, Zihao Zheng, Michael R Lasarev, Michele C Larsen, Addie Vande Loo, Roxana A Alexandridis, Michael A Newton, Miriam A Shelef, Sara S McCoy
Objectives Sjögren disease (SjD) diagnosis often requires either positive anti-SSA antibodies or a labial salivary gland biopsy with a positive focus score (FS). One-third of patients with SjD lack anti-SSA antibodies (SSA−), requiring a positive FS for diagnosis. Our objective was to identify novel autoantibodies to diagnose ‘seronegative’ SjD. Methods IgG binding to a high-density whole human peptidome
-
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-03 Tina Baker, Hoda Sharifian, Paul J Newcombe, Patrick G Gavin, Mark N Lazarus, Madhu Ramaswamy, Wendy I White, Nicola Ferrari, Daniel Muthas, Raj Tummala, Eric F Morand, Richard Furie, Edward M Vital, Chris Chamberlain, Adam Platt, Hussein Al-Mossawi, Philip Z Brohawn, Eszter Csomor
Introduction Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab using longitudinal transcriptomic and proteomic analyses of the 52-week, randomised, phase 3 TULIP-1 and TULIP-2 trials. Methods Patients with moderate to severe SLE were
-
Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-03 Irina Gessl, Garifallia Sakellariou, Brigitte Wildner, Georgios Filippou, Peter Mandl, Maria Antonietta D’Agostino, Victoria Navarro-Compán
Objective To summarise current data regarding the use of imaging in crystal-induced arthropathies (CiAs) informing a European Alliance of Associations for Rheumatology task force. Methods We performed four systematic searches in Embase, Medline and Central on imaging for diagnosis, monitoring, prediction of disease severity/treatment response, guiding procedures and patient education in gout, calcium
-
Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-30 Kader Cetin Gedik, Ana M Ortega-Villa, Grace Materne, Andre Rastegar, Gina A Montealegre Sanchez, Adam Reinhardt, Paul A Brogan, Yackov Berkun, Sara Murias, Maria Robles, Susanne Schalm, Adriana A de Jesus, Raphaela Goldbach-Mansky
Objectives Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at exposures higher than in rheumatoid arthritis. Baricitinib dose reductions to minimise exposure triggered disease flares which we used to develop ‘flare criteria’
-
Is tooth extraction as proxy for periodontal disease related to the development of RA? Lessons from a longitudinal study in the at-risk stage of clinically suspect arthralgia Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-30 Sarah J H Khidir, René E M Toes, Elise van Mulligen, Annette H M van der Helm-van Mil
Emerging evidence points to the involvement of periodontal disease (PD) in the pathogenesis of rheumatoid arthritis (RA), especially in anti-citrullinated protein antibodies (ACPA)-positive RA. The bacteria Porphyromonas gingivalis , involved in oral mucosal inflammation and PD, can citrullinate proteins via prokaryotic peptidylarginine deiminase.1 Systemic translocation of oral bacteria has been found
-
Vascular disease persistence in giant cell arteritis: are stromal cells neglected? Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-29 Maira Karabayas, Hafeez E Ibrahim, Anke J Roelofs, Gary Reynolds, Dana Kidder, Cosimo De Bari
Giant cell arteritis (GCA), the most common systemic vasculitis, is characterised by aberrant interactions between infiltrating and resident cells of the vessel wall. Ageing and breach of tolerance are prerequisites for GCA development, resulting in dendritic and T-cell dysfunction. Inflammatory cytokines polarise T-cells, activate resident macrophages and synergistically enhance vascular inflammation
-
Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc) Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-29 Minrui Liang, Lingbiao Wang, Xiaolong Tian, Kun Wang, Xiaoyi Zhu, Linlin Huang, Qing Li, Wenjing Ye, Chen Chen, Haihua Yang, Wanqing Wu, Xiangjun Chen, Xiaoxia Zhu, Yu Xue, Weiguo Wan, Yanling Wu, Liwei Lu, Jiucun Wang, Hejian Zou, Tianlei Ying, Feng Zhou
Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to employ a global antibody profiling strategy to identify novel antibodies and investigate their association with systemic sclerosis (SSc). Methods We implemented this strategy by conducting immunoprecipitation
-
No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-23 Eirik Ikdahl, Anne Grete Semb, Anne M Kerola
The risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) is closely linked to increasing levels of systemic inflammation.1 However, little is known about the CVD risk in patients with RA who maintain stable disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the CVD risk in seropositive patients with RA who retained their first DMARD with no corticosteroid
-
bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-23 Peter Kvacskay, Ute Hegenbart, Hanns-Martin Lorenz, Stefan O Schönland, Norbert Blank
Introduction AA amyloidosis (AA) can be the consequence of any chronic inflammatory disease. AA is associated with chronic inflammatory diseases (cid+AA), autoinflammatory syndromes (auto+AA) or AA of unknown origin or idiopathic AA (idio+AA). The major organ manifestation is renal AA that can progress to end-stage renal disease (ESRD) and multiple organ failure. Materials and methods This study is
-
Retraction: PKCδ null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-22 BMJ Publishing Group Ltd and European League Against Rheumatism
Kc R, Li X, Kroin JS, et al. PKCδ null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal …
-
Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-18 Andrea R Daamen, Peter E Lipsky
Chimeric antigen receptors (CARs) are synthetic proteins designed to direct an immune response toward a specific target and have been used in immunotherapeutic applications through the adoptive transfer of T cells genetically engineered to express CARs. This technology received early attention in oncology with particular success in treatment of B cell malignancies leading to the launch of numerous
-
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-12 Dionysis Nikolopoulos, Catherine Loukogiannaki, George Sentis, Panagiotis Garantziotis, Theodora Manolakou, Noemin Kapsala, Myrto Nikoloudaki, Antigone Pieta, Sofia Flouda, Ioannis Parodis, George Bertsias, Antonis Fanouriakis, Anastasia Filia, Dimitrios T Boumpas
Introduction Systemic lupus erythematosus with antiphospholipid syndrome (SLE-APS) represents a challenging SLE endotype whose molecular basis remains unknown. Methods We analysed whole-blood RNA-sequencing data from 299 patients with SLE (108 SLE-antiphospholipid antibodies (aPL)-positive, including 67 SLE-APS; 191 SLE-aPL-negative) and 72 matched healthy controls (HC). Pathway enrichment analysis
-
Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Désirée van der Heijde, Anna Molto, Sofia Ramiro, Jürgen Braun, Maxime Dougados, Floris A van Gaalen, Lianne S Gensler, Robert D Inman, Robert B M Landewé, Helena Marzo-Ortega, Victoria Navarro-Compán, Andri Phoka, Denis Poddubnyy, Mikhail Protopopov, John Reveille, Martin Rudwaleit, Percival Sampaio-Barros, Alexandre Sepriano, Joachim Sieper, Filip E Van den Bosch, Irene van der Horst-Bruinsma, Pedro
Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis as a dominant characteristic. However, with the availability of MRI of SIJ, it could be demonstrated that the disease starts long before definite SIJ changes become visible
-
Shift in perspective: autoimmunity protecting against rheumatoid arthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Yibo He, Mike Aoun, Zhongwei Xu, Rikard Holmdahl
A hallmark of rheumatoid arthritis (RA) is the increased levels of autoantibodies preceding the onset and contributing to the classification of the disease. These autoantibodies, mainly anti-citrullinated protein antibody (ACPA) and rheumatoid factor, have been assumed to be pathogenic and many attempts have been made to link them to the development of bone erosion, pain and arthritis. We and others
-
Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Cynthia S Crowson, Elizabeth J Atkinson, Vanessa L Kronzer, Bradly A Kimbrough, Courtney A Arment, Lynne S Peterson, Kerry Wright, Thomas G Mason, Delamo I Bekele, John M Davis, Elena Myasoedova
Objectives We aimed to cluster patients with rheumatoid arthritis (RA) based on comorbidities and then examine the association between these clusters and RA disease activity and mortality. Methods In this population-based study, residents of an eight-county region with prevalent RA on 1 January 2015 were identified. Patients were followed for vital status until death, last contact or 31 December 2021
-
EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3 Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Gan Wu, Ben Cao, Haige Zhai, Bin Liu, Yuan Huang, Xiaowei Chen, Hanzhi Ling, Sunwang Ling, Shengwei Jin, Xinyu Yang, Jianguang Wang
Objective Erythropoietin (EPO) known as an erythrocyte-stimulating factor is increased in patients with rheumatoid arthritis (RA). Nevertheless, the function of EPO in the process of RA and relative mechanism needs to be further clarified. Methods The level of EPO in serum and synovial fluid from patients with RA and healthy controls was determined by . Collagen-induced arthritis (CIA) mice were constructed
-
Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-α in rheumatoid arthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Fanlei Hu, Lianjie Shi, Xiaohang Liu, Yingjia Chen, Xia Zhang, Yuan Jia, Xu Liu, Jianping Guo, Huaqun Zhu, Hongjiang Liu, Liling Xu, Yingni Li, Ping Wang, Xiangyu Fang, Jimeng Xue, Yang Xie, Chaonan Wei, Jing Song, Xi Zheng, Yan-Ying Liu, Yuhui Li, Limin Ren, Dakang Xu, Liwei Lu, Xiaoyan Qiu, Rong Mu, Jing He, Min Wang, Xuan Zhang, Wanli Liu, Zhanguo Li
Objectives B10 and B10pro cells suppress immune responses via secreting interleukin (IL)-10. However, their regulators and underlying mechanisms, especially in human autoimmune diseases, are elusive. This study aimed to address these questions in rheumatoid arthritis (RA), one of the most common highly disabling autoimmune diseases. Methods The frequencies and functions of B10 and B10pro cells in healthy
-
Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Mary Lucy Marques, Sofia Ramiro, Miranda van Lunteren, Rosalinde Anne Stal, Robert BM Landewé, Marleen van de Sande, Karen Minde Fagerli, Inger Jorid Berg, Maikel van Oosterhout, Sofia Exarchou, Roberta Ramonda, Désirée van der Heijde, Floris A van Gaalen
Objectives To investigate the prevalence of axial spondyloarthritis (axSpA) in patients with chronic back pain (CBP) of less than 2 years (2y) duration referred to the rheumatologist, the development of diagnosis over time, and patient characteristics of those developing definite (d-)axSpA over 2y. Methods We analysed the 2y data from SPondyloArthritis Caught Early, a European cohort of patients (<45 years)
-
Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Fabian Proft, Murat Torgutalp, Burkhard Muche, Valeria Rios Rodriguez, Joachim Listing, Mikhail Protopopov, Judith Rademacher, Hildrun Haibel, Laura Spiller, Anne-Katrin Weber, Maryna Verba, Jan Brandt-Juergens, Uta Kiltz, Maren Sieburg, Swen Jacki, Joachim Sieper, Denis Poddubnyy
Objectives The study aimed to evaluate the effect of adding a non-steroidal anti-inflammatory drug (NSAID), celecoxib (CEL), to a tumour necrosis factor inhibitor (TNFi), golimumab (GOL), compared with TNFi monotherapy on radiographic spinal progression in patients with radiographic axial spondyloarthritis (r-axSpA) over 2 years. Methods R-axSpA patients, having risk factors for radiographic progression
-
Single-cell profiling reveals kidney CD163+ dendritic cell participation in human lupus nephritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Wei Chen, Bei Jin, Cheng Cheng, Huajing Peng, Xinxin Zhang, Weiping Tan, Ruihan Tang, Xingji Lian, Hui Diao, Ning Luo, Xiaoyan Li, Jinjin Fan, Jian Shi, Changjun Yin, Ji Wang, Sui Peng, Li Yu, Jun Li, Rui-Qi Wu, Dong-Ming Kuang, Guo-Ping Shi, Yi Zhou, Fang Wang, Xiaoyun Jiang
Objectives The current work aimed to provide a comprehensive single-cell landscape of lupus nephritis (LN) kidneys, including immune and non-immune cells, identify disease-associated cell populations and unravel their participation within the kidney microenvironment. Methods Single-cell RNA and T cell receptor sequencing were performed on renal biopsy tissues from 40 patients with LN and 6 healthy
-
Single-cell transcriptome analyses reveal disturbed decidual homoeostasis in obstetric antiphospholipid syndrome Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Chenyang Lu, Rui Gao, Pingying Qing, Xun Zeng, Xin Liao, Meng Cheng, Lang Qin, Yi Liu
Objectives Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease characterised by the presence of antiphospholipid antibodies in circulation and pathological pregnancy. However, the pathogenesis of OAPS remains unknown. We aimed to reveal cellular compositions and molecular features of decidual cells involved in the development of OAPS using single-cell RNA sequencing (scRNA-seq). Methods
-
Deep immunophenotyping reveals that autoimmune and autoinflammatory disorders are spread along two immunological axes capturing disease inflammation levels and types Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Nicolas Tchitchek, Marie Binvignat, Alexandra Roux, Fabien Pitoiset, Johanna Dubois, Gwendolyn Marguerit, David Saadoun, Patrice Cacoub, Jérémie Sellam, Francis Berenbaum, Agnès Hartemann, Chloé Amouyal, Roberta Lorenzon, Encarnita Mariotti-Ferrandiz, Michelle Rosenzwajg, David Klatzmann
Objectives Based on genetic associations, McGonagle and McDermott suggested a classification of autoimmune and autoinflammatory diseases as a continuum ranging from purely autoimmune to purely autoinflammatory diseases and comprising diseases with both components. We used deep immunophenotyping to identify immune cell populations and molecular targets characterising this continuum. Methods We collected
-
Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Linyi Peng, Yuxue Nie, Jiaxin Zhou, Lijun Wu, Xiaomei Chen, Fang Wang, Jieqiong Li, Yu Peng, Hui Lu, Lidan Zhao, Mengtao Li, Yan Zhao, Xiaofeng Zeng, Yunyun Fei, Wen Zhang
Objectives IgG4-related disease (IgG4-RD) is an immune-mediated, fibroinflammatory disease. Induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy for maintenance treatment a challenge. The WInS IgG4-RD (withdraw immunosuppressants (IMs) and steroid in stable IgG4-RD) trial tested whether discontinuation of GC and IM was feasible in stable
-
Prognostic model to predict the incidence of radiographic knee osteoarthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Rocío Paz-González, Vanesa Balboa-Barreiro, Lucia Lourido, Valentina Calamia, Patricia Fernandez-Puente, Natividad Oreiro, Cristina Ruiz-Romero, Francisco J Blanco
Objective Early diagnosis of knee osteoarthritis (KOA) in asymptomatic stages is essential for the timely management of patients using preventative strategies. We develop and validate a prognostic model useful for predicting the incidence of radiographic KOA (rKOA) in non-radiographic osteoarthritic subjects and stratify individuals at high risk of developing the disease. Methods Subjects without radiographic
-
Associations of residential greenness with bone mineral density and osteoporosis: the modifying effect of genetic susceptibility Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Tingting Tan, Linxi Tang, Xiaoning Guo, Tao Li, Yaohua Tian, Zhengxiao Ouyang
Objectives To investigate the associations of residential greenness with bone mineral density and incident osteoporosis, and further evaluate the potential modifying effect of genetic susceptibility. Methods We used the Normalised Difference Vegetation Index (NDVI) at various buffer distances, including 300 m (NDVI300m), 500 m (NDVI500m), 1000 m (NDVI1000m) and 1500 m (NDVI1500m), to serve as indicators
-
Vasculitis that did not read the books Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Ana C Bardan-Inchaustegui, Jorge A Esquivel-Valerio, Rodrigo de Jesus Castillo-de la Garza, Jesus Alberto Cardenas-de la Garza, Valeria Gonzalez-Gonzalez, Dionicio Angel Galarza-Delgado
A 29-year-old woman presented to our rheumatology clinic with a 6-month history of cough, dysphonia, dyspnoea and weight loss. She also complained of a lump in her throat (globus pharyngeus), left otalgia and hearing loss. One month before evaluation, she started experiencing blood-tinged sputum and dyspnoea. On clinical examination, the patient had nasal discharge, crusting and congestion, laryngeal
-
Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Jérôme Avouac, Sophie Hecquet, Marion Thomas, Alice Combier, Sandrine Carvès, Yannick Allanore
New definitions for flares in rheumatoid arthritis (RA) based on the Simplified and Clinical Disease Activity Indices (SDAI, CDAI) have been recently introduced.1 In this article, the authors defined flare as an absolute increase of 4.7 in SDAI and 4.5 in CDAI. Following this proposal we aimed at studying these cut-off values for absolute increases in SDAI and CDAI in diagnosing self-reported flares
-
Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Abigail E Schiff, Xiaosong Wang, Naomi J Patel, Yumeko Kawano, Jennifer L Hanberg, Emily N Kowalski, Claire E Cook, Kathleen MM Vanni, Grace Qian, Katarina J Bade, Alene A Saavedra, Shruthi Srivatsan, Zachary K Williams, Rathnam K Venkat, Zachary S Wallace, Jeffrey A Sparks
The US Centers for Disease Control and Prevention (CDC) recommends three SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine doses, rather than two, to complete the initial vaccine series for immunosuppressed patients. However, they may remain at risk for breakthrough COVID-19 due to immunomodulators that blunt vaccine responses.1 Identifying patients at highest risk for breakthrough COVID-19 can
-
Gender imbalance in expert panels of recommendations in rheumatology Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 Xufei Luo, Yaxuan Ren, Yaolong Chen
Gender imbalance is a major source of inequity in the society. Inequality is an enduring topic also in medical research, as disparities in the participation of individuals based on their gender may potentially influence the research outcomes. Gender inequality often manifests as a lower representation of women as study authors or even their complete absence from research teams. Underlying causes may
-
Correction: Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-05-01 BMJ Publishing Group Ltd and European League Against Rheumatism
Morand EF, Abreu G, Furie RA, et al . Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the Rheumatic Diseases 2023;82:639-645. This note aims to correct an error in the DORIS (Definition of Remission in SLE) data in the Morand E, et al . (2023) article. In the version of this article initially published, analyses
-
Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-09 Caitríona Grönberg, Sara Rattik, Cuong Tran-Manh, Xiang Zhou, Aleix Rius Rigau, Yi-Nan Li, Andrea-Hermina Györfi, Nicholas Dickel, Meik Kunz, Alexander Kreuter, Emil-Alexandru Matei, Honglin Zhu, Petter Skoog, David Liberg, Jörg HW Distler, Thuong Trinh-Minh
Background The interleukin (IL)-1 receptor accessory protein (IL1RAP) is an essential coreceptor required for signalling through the IL-1, IL-33 and IL-36 receptors. Here, we investigate the antifibrotic potential of the combined inhibition of these cytokines by an anti-IL1RAP antibody to provide a scientific background for clinical development in systemic sclerosis (SSc). Methods The expression of
-
Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-09 Ji-Won Kim, Jun Sik Yoon, Sojeong Park, Hasung Kim, Ji Sung Lee, Jung-Yoon Choe
Objective To investigate the risk of cardiovascular disease (CVD) associated with increasing dose of a non-steroidal anti-inflammatory drug (NSAID) in patients with ankylosing spondylitis (AS). Methods Using the Korean National Health Insurance database, patients newly diagnosed with AS without prior CVD between 2010 and 2018 were included in this nationwide cohort study. The primary outcome was CVD
-
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-09 Blanca Hernández-Cruz, Lucía Otero-Varela, Mercedes Freire-González, Noemí Busquets-Pérez, Alfredo Javier García González, Manuel Moreno-Ramos, Juan Maria Blanco-Madrigal, Sara Manrique-Arija, Eva Perez-Pampin, Dolores Ruiz-Montesino, Fernando Sánchez-Alonso, Carlos Sanchez-Piedra, Isabel Castrejón
Objectives To compare the safety of Janus kinase inhibitors (JAKi) with that of tumour necrosis factor inhibitors (TNFi) and determine drug persistence among patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA). Methods We analysed data from patients included in BIOBADASER 3.0 and treated with JAKi or TNFi from 2015 to 2023 and estimated the incidence rate ratio (IRR) of adverse events
-
Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-05 Antonis Fanouriakis, Myrto Kostopoulou, George Bertsias, Dimitrios T Boumpas
We thank Dr Kronbichler et al for their interest in the recent update of the EULAR recommendations for systemic lupus erythematosus (SLE),1 and for bringing up an important aspect in the management of lupus nephritis (LN).2 The authors, who are all expert nephrologists, highlight the importance of adjunct treatment in LN beyond sole immunosuppression, with an emphasis on the potential use of sodium-glucose
-
Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis et al Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-05 Andreas Kronbichler, Hans-Joachim Anders, Eleni Frangou, Safak Mirioglu, Balazs Odler, Luis F Quintana, María José Soler Romeo, Annette Bruchfeld
The recently published European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) (2023 update)1 recognise the major achievements in treating lupus nephritis (LN). These include the approval of two newer agents, belimumab and voclosporin, which can be used as add-on therapies and have proved effective in the phase III trials BLISS-LN
-
Development and evaluation of a text analytics algorithm for automated application of national COVID-19 shielding criteria in rheumatology patients Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-04 Meghna Jani, Ghada Alfattni, Maksim Belousov, Lynn Laidlaw, Yuanyuan Zhang, Michael Cheng, Karim Webb, Robyn Hamilton, Andrew S Kanter, William G Dixon, Goran Nenadic
Introduction At the beginning of the COVID-19 pandemic, the UK’s Scientific Committee issued extreme social distancing measures, termed ‘shielding’, aimed at a subpopulation deemed extremely clinically vulnerable to infection. National guidance for risk stratification was based on patients’ age, comorbidities and immunosuppressive therapies, including biologics that are not captured in primary care
-
HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-04 Jürgen Braun, Elisabeth Märker-Hermann, Martin Rudwaleit, Joachim Sieper
The pathogenesis of axial spondyloarthritis (axSpA), although not entirely clear yet, is largely based on genes, the strongest association being with HLA-B27, importantly also in connection with aminopeptidase ERAP 1 polymorphisms. Peptides potentially derived from microbes and/or autoantigens presented by HLA-B27 expressed on antigen-presenting cells to CD8+T cells are thought to play a critical role
-
Validation and incorporation of digital entheses into a preliminary GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-04 Esperanza Naredo, Maria Antonietta D'Agostino, Lene Terslev, Carlos Pineda, M Isabel Miguel, Joan Blasi, George A Bruyn, Marion C Kortekaas, Peter Mandl, Rodina Nestorova, Marcin Szkudlarek, Plamen Todorov, Violeta Vlad, Priscilla Wong, Catherine Bakewell, Emilio Filippucci, Alen Zabotti, Mihaela Micu, Florentin Vreju, Mohamed Mortada, José Alexandre Mendonça, Carlos A Guillen-Astete, Otto Olivas-Vergara
Objectives The main objective was to generate a GLobal OMERACT Ultrasound DActylitis Score (GLOUDAS) in psoriatic arthritis and to test its reliability. To this end, we assessed the validity, feasibility and applicability of ultrasound assessment of finger entheses to incorporate them into the scoring system. Methods The study consisted of a stepwise process. First, in cadaveric specimens, we identified
-
Response to: Correspondence on ‘EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update’ by Hellmich et al Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-03 Bernhard Hellmich, David Jayne
We wish to thank Robson et al for emphasising the role of shared decision-making between healthcare providers and patients with ANCA-associated vasculitides (AAV).1 For the first time, a statement on shared decision-making in the care of patients with AAV was introduced to the European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of AAV with its most recent update
-
Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Karolina Gente, Manuel Feisst, Dorothea Marx, Karel D Klika, Petros Christopoulos, Jürgen Graf, Julia Will, Thomas Luft, Jessica C Hassel, Carsten Müller-Tidow, Rui A Carvalho, Hanns-Martin Lorenz, M Margarida Souto-Carneiro
Objectives A timely diagnosis is imperative for curing cancer. However, in patients with rheumatic musculoskeletal diseases (RMDs) or paraneoplastic syndromes, misleading symptoms frequently delay cancer diagnosis. As metabolic remodelling characterises both cancer and RMD, we analysed if a metabolic signature can indicate paraneoplasia (PN) or reveal concomitant cancer in patients with RMD. Methods
-
Response to: Correspondence on ‘Current myositis clinical trials and tribulations’ by Saygin et al Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-28 Didem Saygin, Victoria Werth, Julie J Paik, Jin Kyun Park, Merrilee Needham, Ingrid E Lundberg, Lisa Christopher-Stine
We thank Azevedo et al 1 for their correspondence in response to the publication of our viewpoint entitled ‘Myositis Clinical Trials and Tribulations’.2 The authors eloquently discuss additional clinical trial designs and analytical approaches that can increase the likelihood of participants being assigned to the treatment arm and facilitate drug approval in idiopathic inflammatory myopathies (IIM)
-
Correspondence on ‘Current myositis clinical trials and tribulations’ by Saygin et al Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-28 Sofia Ferreira Azevedo, Antonia Valenzuela, Cristian Alejandro Benitez, David A Isenberg, Elie Naddaf, Hector Chinoy, Jiří Vencovský, Latika Gupta, Liza McCann, Masataka Kuwana, Mazen M Dimachkie, Susan Shenoi, Lesley Ann Saketkoo, Pedro M Machado
We read the viewpoint titled ‘current myositis clinical trials and tribulations’ with great interest.1 We congratulate the authors for addressing critical patient-centred and science-forward concerns in idiopathic inflammatory myopathies (IIMs) clinical trials. These valuable insights highlight current pitfalls and the need for more effective engagement of patients, physicians and trial methodology
-
Should all patients with polymyalgia rheumatica have a vascular ultrasound assessment? Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-29 Sharon Cowley, Patricia Harkins, Colm Kirby, Richard Conway, David J Kane
There is a growing appreciation that both giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely interrelated conditions that have significant overlap in aetiology, clinical characteristics and treatment regimens. Subclinical GCA in PMR is becoming increasingly recognised, and there is evolving evidence that this may be a more aggressive disease phenotype than PMR. Ultrasound (US)
-
Gender equity in global rheumatology awards Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-26 Debaditya Roy, Laura Andreoli, Pavel V Ovseiko, Dzifa Dey, Yuva Ravindran, Shikha Singla, Ana María Arredondo González, Carlos Enrique Toro-Gutiérrez, Latika Gupta
Globally, there has been a growing interest in addressing gender disparities in leadership positions within rheumatology,1 editorial boards of rheumatology journals,2 conference speakers3 and authorship of research publications and guidelines.4 5 The causes of gender disparity in rheumatology are complex and multifactorial, including an interplay of historically late entrance of a larger number of
-
Characterisation of choroid plexus-infiltrating T cells reveals novel therapeutic targets in murine neuropsychiatric lupus Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-26 Erica Moore, Sushma Bharrhan, Deepak A Rao, Fernando Macian, Chaim Putterman
Objective Diffuse central nervous system manifestations, referred to as neuropsychiatric lupus (NPSLE), are observed in 20–40% of lupus patients and involve complex mechanisms that have not yet been adequately elucidated. In murine NPSLE models, choroid plexus (ChP)-infiltrating T cells have not been fully evaluated as drivers of neuropsychiatric disease. Method Droplet-based single-cell transcriptomic
-
Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren’s disease Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-25 Sarthak Gupta, Eiko Yamada, Hiroyuki Nakamura, Paola Perez, Thomas JF Pranzatelli, Kalie Dominick, Shyh-Ing Jang, Mehdi Abed, Daniel Martin, Peter Burbelo, ChangYu Zheng, Ben French, Ilias Alevizos, Zohreh Khavandgar, Margaret Beach, Eileen Pelayo, Brian Walitt, Sarfaraz Hasni, Mariana J Kaplan, Mayank Tandon, Maria Teresa Magone, David E Kleiner, John A Chiorini, Alan Baer, Blake M Warner
Objectives Inflammatory cytokines that signal through the Janus kinases–signal transducer and activator of transcription (JAK-STAT) pathway, especially interferons (IFNs), are implicated in Sjögren’s disease (SjD). Although inhibition of JAKs is effective in other autoimmune diseases, a systematic investigation of IFN-JAK-STAT signalling and the effect of JAK inhibitor (JAKi) therapy in SjD-affected
-
MRI-based synthetic CT: a new method for structural damage assessment in the spine in patients with axial spondyloarthritis – a comparison with low-dose CT and radiography Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-20 Simone Tromborg Willesen, Anna EF Hadsbjerg, Jakob Møllenbach Møller, Nora Vladimirova, Bimal M K Vora, Sengül Seven, Susanne Juhl Pedersen, Mikkel Østergaard
Objective To investigate the ability of MRI-based synthetic CT (sCT), low-dose CT (ldCT) and radiography to detect spinal new bone formation (NBF) in patients with axial spondyloarthritis (axSpA). Methods Radiography of lumbar and cervical spine, ldCT and sCT of the entire spine were performed in 17 patients with axSpA. sCT was reconstructed using the BoneMRI application (V.1.6, MRIGuidance BV, Utrecht
-
Fever, low back pain and skin ulcerations Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-20 Linrong He, Yongpeng Ge, Xiaoming Shu
A 43-year-old woman was hospitalised with 21 days of fever, severe low back pain and 10 days of painful skin lesions involving both knees (panel A and B) (figure 1) in succession. The lesions emerged as erythema, then blistered and ulcerated rapidly with a necrolytic, undermined violaceous border that did not respond to antimicrobial therapy. She had an 8-year history of poorly controlled ulcerative
-
Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-19 Pang Lyu, Jinming Wen, Wenshuo Zhang, Ning Liu, Iris Stolzer, Andreas Gießl, Yewei Jia, Daniele Mauro, Fulin Zhang, Francesco Ciccia, Didier Soulat, Claudia Günther, Georg Schett, Aline Bozec
Objectives To investigate the mechanism by which intestinal epithelial cell (IEC) death induces arthritis. Methods IEC death was assessed by staining for necroptosis and apoptosis markers and fluorescence in situ hybridisation at different time points during collagen-induced arthritis (CIA). During the development of CIA, messenger RNA (mRNA) sequencing was performed, followed by Gene Ontology enrichment
-
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-19 Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Jan W Schoones, Laure Gossec
Objectives To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). Methods This systematic literature research (SLR) investigated the efficacy and safety of conventional synthetic (cs), biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in patients with PsA. A systematic database search using
-
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-18 Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, Annamaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele
Objective New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of
-
Clinical image: tophus in the sternoclavicular joint Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-13 Si Chen, Fengjing Liu, Jie Chen, Geng Gu, Haoyong Yu
A 51-year-old man presented with persistent pain localised to the right clavicle after consuming 1600 mL of beer. The patient has a medical history of gout but no history of trauma or infection at the lesion site. Physical examination showed that the patient’s temperature was of 37.4°C, presenting only pain in the right sternoclavicular joint and no symptoms of pain in any other joint. Laboratory examination
-
Primary osteoarthritis chondrocyte map of chromatin conformation reveals novel candidate effector genes Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-03-13 Norbert Bittner, Chenfu Shi, Danyun Zhao, James Ding, Lorraine Southam, Diane Swift, Peter Kreitmaier, Mauro Tutino, Odysseas Stergiou, Jackson T S Cheung, Georgia Katsoula, Jenny Hankinson, Jeremy Mark Wilkinson, Gisela Orozco, Eleftheria Zeggini
Objectives Osteoarthritis is a complex disease with a huge public health burden. Genome-wide association studies (GWAS) have identified hundreds of osteoarthritis-associated sequence variants, but the effector genes underpinning these signals remain largely elusive. Understanding chromosome organisation in three-dimensional (3D) space is essential for identifying long-range contacts between distant
-
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023 Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John D Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie Crofford, Ronald F van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Tom WJ Huizinga, Ellen M Gravallese
The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology
-
Morris Ziff Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Philip Cohen, David Ziff, Peter E Lipsky
We, rheumatologists, practise in an era when the study of rheumatic diseases and the care of affected patients are rooted in rigorous scientific investigation. This was not the case before the mid-20th century, when Dr Morris Ziff and a few other Pillars of Rheumatology pioneered the application of rigorous basic and clinical science to a nascent field, in which affected people were often regarded
-
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study) Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Romain Aymon, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, Diederik De Cock, Lene Dreyer, Ori Elkayam, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun Inanc, Lianne Kearsley-Fleet, Suleyman Serdar KOCA, Tore K Kvien, Burkhard F Leeb, Galina Lukina, Dan C Nordström, Karel Pavelka, Manuel Pombo-Suarez, Ana Rodrigues, Ziga Rotar, Anja Strangfeld, Patrick Verschueren
Background In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis factor inhibitors (TNFi) adalimumab or etanercept. Objective Compare treatment discontinuations for adverse events (AEs) among second-line therapies in an international real-world
-
Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Joshua F Baker, James R ODell, Bryant R England, Jon T Giles, Jefferey A Newcomb, Michael D George, Geoffrey Thiele, Larry Moreland, S Louis Bridges, Jeffrey R Curtis, Ted R Mikuls
Purpose To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response. Methods This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and the (TEAR) trial. Both studies compared treatment strategies
-
Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Max M H Teuwen, Salima F E van Weely, Thea P M Vliet Vlieland, Maria A T van Wissen, Wilfred F Peter, Alfons A den Broeder, Dirkjan van Schaardenburg, Wilbert B van den Hout, Cornelia H M Van den Ende, Maaike G J Gademan
Objectives To compare the effectiveness of longstanding (>52 weeks), supervised exercise therapy with usual care in adults with rheumatoid arthritis (RA) and severe functional limitations. Methods Participants were randomised 1:1 to the intervention (individualised goal-setting, active exercises, education and self-management regarding physical activity) or usual care. Primary endpoint was the change
-
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study Ann. Rheum. Dis. (IF 27.4) Pub Date : 2024-04-01 Sofia Exarchou, Daniela Di Giuseppe, Eva Klingberg, Valgerdur Sigurdardottir, Sara Wedrén, Ulf Lindström, Carl Turesson, Lennart T H Jacobsson, Johan Askling, Johan K Wallman
Objectives To compare all-cause mortality and causes of death between patients with psoriatic arthritis (PsA) and the general population in Sweden. Methods Adults with at least one main PsA diagnosis (International Classification of Diseases-10: L40.5/M07.0–M07.3) from outpatient rheumatology/internal medicine departments 2001–2017 were identified from the National Patient Register. Each case was matched